electroCore (NASDAQ:ECOR) is collaborating with Massachusetts General Hospital (MGH) in a neuroinflammation research program. Under the program, electroCore’s non-invasive vagus nerve stimulation (nVNS) will be studied...
A new study published in the peer-reviewed journal, Dysphagia, suggests that the proportion of seniors with swallowing problems in the U.S. is expected to top 20% by 2030 from 15% currently. “Dysphagia has...
Titan Pharmaceuticals (NASDAQ:TTNP) has entered into an amendment of an earlier asset purchase, supply and support agreement with L. Molteni & C. dei F.lli Alitti Società di Esercizio S.p.A., which allowed Molteni...
Closely-held Vasomune Therapeutics and AnGes (Tokyo, TYO:4563) signed a global co-development agreement for the development and commercialization of therapeutics treating diseases associated with blood vessel...
PharmaJet and Mundipharma have inked an exclusive partnership to market and distribute PharmaJet’s Tropis and Stratis needle-free drug-delivery devices to more than 120 markets around the world. The devices are designed...
Synexus, a leading global network of research sites, is collaborating with the University of Exeter in the UK to launch one of the largest, registry-based research initiatives in the U.S. to help understand how healthy...
Israel-based Respinova has won the second grant offered by Chiesi Spain and Richi Entrepreneurs to promote an innovative project that directly impacts treatment and quality of life of patients with chronic obstructive...
Imagin Medical (CSE:IME; OTCQB:IMEXF) reported favorable results in a 10-subject investigator-sponsored research study at the University of Rochester Medical Center (URMC) using the i/Blue Imaging System, an important...
Profound Medical (TSXV:PRN; OTCQX:PRFMF) has received final approval to list its common shares on the Toronto Stock Exchange, effective at the opening on July 13, 2018. The stock will continue to trade under the symbol...
A study published in the scientific journal, npj Parkinson’s Disease, estimates that 930,000 people in the U.S. will be living with the disease by 2020, further increasing to 1.2 million people by 2030. “Our...